BioNexus Gene Lab appoints Dr. Muthu Meyyappan as CCO of Fidelion

BioNexus Gene Lab Corp. (NASDAQ: BGLC) announced the appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics Pte. Ltd., according to a company statement.

Fidelion is a precision diagnostics company focused on oncology testing technologies, including minimal residual disease liquid biopsy assays. The company serves as the international commercialization vehicle for the VitaGuard MRD technology developed by Tongshu Gene, supporting initiatives outside Greater China. BioNexus Gene Lab holds exclusive commercialization rights for VitaGuard across Southeast Asia through its licensing arrangement with Fidelion.

Dr. Meyyappan will lead Fidelion's global commercial strategy and partnerships, including the development of clinical, laboratory, and pharmaceutical collaborations. He brings over 15 years of experience in precision oncology diagnostics, genomics, and liquid biopsy commercialization.

Previously, Dr. Meyyappan served as Global Chief Commercial Officer at Menarini Silicon Biosystems, where he worked on expanding oncology diagnostics business and supporting commercial adoption of liquid biopsy and MRD-related diagnostic platforms. He also held the position of Chief Commercial Officer at Variantyx, leading the global commercial launch of the Genomic Unity whole-genome sequencing platform. His earlier roles included senior commercial positions at Congenica and QIAGEN.

Dr. Meyyappan holds a Ph.D. in Cancer Biology from the University of Calgary and a Bachelor of Science in Biotechnology from the Rochester Institute of Technology.

"Dr. Meyyappan brings extensive experience in scaling oncology diagnostics and genomics businesses globally," said Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp.

BioNexus Gene Lab is a strategic investor in Fidelion and operates as a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging technology platforms.

You May Also Be Interested In

• Sera Prognostics names Scott Gleason as CFO, effective Aug. 31
• Singularity Future Technology closes $1.8M registered direct offering
• Baxter names John Rogers as CFO, effective October 2026